目的:为了研究大剂量静脉(IV)铁的肝脏效应,包括肝功能和纤维化程度,在肝硬化的大鼠模型中。
方法:我们将25只Sprague-Dawley大鼠均匀分为5组:正常大鼠(对照组),肝硬化大鼠接受静脉生理盐水(肝硬化[LC]组),和肝硬化大鼠接受20、40或80mg/kg静脉铁羧基麦芽糖(LC-iron20,LC-iron40和LC-iron80组,分别)。在0、7、14、21和28天比较生化参数。评估肝纤维化和铁沉积的程度。还比较了炎症和氧化应激标志物。
结果:LC-iron20,LC-iron40和LC-iron80组的28天血清丙氨酸转氨酶水平没有显着差异(对照组为69±7、1003±127、1064±309、919±346和820±195/IU,LC,LC-iron20、LC-iron40和LC-iron80基团,分别)。肝脏铁积累以剂量依赖性方式增加,但各组之间的肝纤维化程度相当。根据IV铁剂量,炎症和氧化应激标志物水平没有显着差异。
结论:在我们的肝硬化大鼠模型中,以各种高剂量给予静脉铁似乎是安全的。
OBJECTIVE: To investigate the hepatic effects of high-dose intravenous (IV) iron, including those on liver function and the degree of fibrosis, in a rat model of cirrhosis.
METHODS: We evenly allocated 25 Sprague-Dawley rats into five groups: normal rats (control group), cirrhotic rats receiving IV normal saline (liver cirrhosis [LC] group), and cirrhotic rats receiving 20, 40, or 80 mg/kg IV ferric carboxymaltose (LC-iron20, LC-iron40, and LC-iron80 group, respectively). Biochemical parameters were compared at 0, 7, 14, 21, and 28 days. The degrees of hepatic fibrosis and iron deposition were evaluated. Inflammatory and oxidative stress markers were also compared.
RESULTS: There were no significant differences in the 28-day serum alanine aminotransferase levels among the LC-iron20, LC-iron40, and LC-iron80 groups (69 ± 7, 1003 ± 127, 1064 ± 309, 919 ± 346, and 820 ± 195 IU/L in the control, LC, LC-iron20, LC-iron40, and LC-iron80 groups, respectively). Hepatic iron accumulation increased in a dose-dependent manner, but the degree of hepatic fibrosis was comparable among the groups. The inflammatory and oxidative stress marker levels did not differ significantly according to the IV iron dose.
CONCLUSIONS: Administration of IV iron at various high doses appears safe in our rat model of cirrhosis.